for posting in the weekly Sentinel newsletter
The First OneMedMarket Conference
On May 21, 2014, the first OneMedMarket conference was held in New York City. Accredited investors turned out from all over for presentations from eleven […]
Sentinel 1
SpectraScience: Innovations in Cancer Detection
SpectraScience has developed patented platform technology that diagnoses colorectal cancer, which has a market size of $1, 442.6 million.
DesignMedix: Overcoming Drug Resistance
DesignMedix places great emphasis on tackling problems of drug resistant diseases, such as malaria, bacteria, and cancer.
First-Mover Healthcare CrowdFunding Portals and Online Investment Firms to Present at 7th Annual OneMedForum San Francisco
OneMedForum announced today that it has assembled two panels featuring early entrants in the emerging areas of crowdfunding and online investment banking in healthcare. Panelists […]
Orexigen: Anti-Obesity Drug Attempting to Enter Multiple Markets
Orexigen Therapeutics is a biopharmaceutical company that focuses its attention on the treatment of one of the most common diseases in existence today, obesity.
ISTO’s Cell Therapies Can Revolutionize Treatment of Joint, Bone Injuries
ISTO Technologies, Inc.is both a regenerative medicine and orthopedics company developing innovative cartilage and bone regeneration products for spinal therapy, sports medicine and trauma. ISTO is currently focused on the development of cell-based cartilage platform technology that can be applied to repair and regenerate damaged cartilage in the knee and spinal disc.
Aridis Pharmaceuticals: Better Alternative to Traditional Antibiotics?
Aridis Pharmaceuticals is a private biotechnology company focusing on improved alternatives to traditional antibiotics for the treatment of pneumonia and Cystic Fibrosis in addition to a few other conditions.
“Regulatory Rush”-The SEC Lifts The Ban On General Solicitation
On July 10th, 2013 new changes to regulations regarding the general solicitation of securities was announced by the Securities and Exchange Commission as the enactment […]
Cognoptix: Simple Eye-Scan Test a Powerful Tool for Diagnosing Alzheimer’s Disease
Cognoptix and its technology have the ability to overhaul commonly accepted Alzheimer’s Disease diagnostic practices, providing a tool to diagnose the disease at an early stage, thereby increasing the efficacy of current therapies.
Complexa: Novel Treatment for Contrast-Induced Acute Kidney Injury
The Contrast Induced Kidney market is a large one, at about $500 million. This is due to the fact that Acute Kidney Injury affects 3-7% of all patients admitted into hospitals and about 25-30% of patients admitted into the Intensive Care Unit. Complexa’s technology has the potential to treat an issue many sick Americans face today.